We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
78 hedge funds and large institutions have $110M invested in Crescent Biopharma in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
0.1% less ownership
Funds ownership: 0.81% → 0.71% (-0.1%)
12% less funds holding
Funds holding: 89 → 78 (-11)
24% less capital invested
Capital invested by funds: $145M → $110M (-$35.1M)
28% less call options, than puts
Call options by funds: $594K | Put options by funds: $826K
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Holders
78
Holders Change
-11
Holders Change %
-12.36%
% of All Funds
1.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
26
Reduced
25
Closed
19
Calls
$594K
Puts
$826K
Net Calls
-$232K
Net Calls Change
+$95K
Top Buyers
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.99M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.39M |
| 3 |
SCM
Sio Capital Management
New York
|
+$1.27M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$760K |
| 5 |
BlackRock
New York
|
+$742K |
